Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. human induced pluripotent stem cell
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Human Induced Pluripotent Stem Cell Articles & Analysis: Older

15 news found

Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Moreover, the company can also provide researchers with cardiac organoid models and human induced pluripotent stem cell (hiPSC) models to support their research into the mechanisms of cardiovascular disease and facilitate the development of effective new drugs and cell therapies. ...

ByAce Therapeutics


BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences

IVS’s Functional 3D tissue models recapitulate the physiological properties of human cardiac, smooth and skeletal muscle and connective tissue. Application of induced pluripotent technology allows to fabricate tissues in diseased states, e.g., hereditary cardiac diseases, cardiac fibrosis, cancer and orphan diseases. ...

ByInvivoSciences, Inc. (IVS)


BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The ultra- sensitive plate reader, CLARIOstar®, will analyze rapid beat-to-beat changes (up to 50 Hz) in the fluorescence intensities of dyes that indicate physiological states ...

ByInvivoSciences, Inc. (IVS)


BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

Ayla Annac, InvivoSciences: InvivoSciences (IVS) is a leading developer of proprietary, award-winning platform technologies that creates human 3D cell/tissue culture models and their automated phenotype analyzers for drug discovery and precision medicine development. ...

ByInvivoSciences, Inc. (IVS)


Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth

Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth

” A leader in contract research, development and manufacturing of human-induced pluripotent stem cell-based solutions (iPSC), Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and ...

ByNcardia Services B.V.


NIH/NIDDK Phase II SBIR Awarded Sept 2015

NIH/NIDDK Phase II SBIR Awarded Sept 2015

Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...

ByRegenerative Medical Solutions Inc. (RMS)


Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Ncardia launches Cellistic, an iPSC cell therapy CDMO

Ncardia launches Cellistic, an iPSC cell therapy CDMO

Ncardia has launched a new business, Cellistic to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. ...

ByNcardia Services B.V.


Dr. Jeanne Loring Joins StemBioSys Scientific Advisory Board; World-renowned leader in Stem Cell Biology

Dr. Jeanne Loring Joins StemBioSys Scientific Advisory Board; World-renowned leader in Stem Cell Biology

Among the many accomplishments of her career, she has led hallmark research studies on differentiating human induced pluripotent stem cells (iPSCs) into neurons that have important applications in treating neurological ...

ByStemBioSys, Inc.


Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality

Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality

Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International ...

ByTreefrog Therapeutics


BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular ...

ByBlueRock Therapeutics


BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular ...

ByOpsis Therapeutics


Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the ...

ByBlueRock Therapeutics


StemBioSys participates in Biotech Showcase Digital during J.P. Morgan Week 2021

StemBioSys participates in Biotech Showcase Digital during J.P. Morgan Week 2021

StemBioSys, Inc., a privately held biomedical company that manufactures and develops innovative, advanced human stem cell technologies to improve the predictive power of pre-clinical drug safety screening, today announced its President and Chief Executive Officer Bob Hutchens will participate in Biotech Showcase Digital being held January ...

ByStemBioSys, Inc.


StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

(Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent ...

ByStemBioSys, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT